RetroSense Therapeutics Completes pre-IND Meeting for RST-001RetroSense Therapeutics, a gene therapy company dedicated to vision restoration, announced completion of a pre-IND meeting with the Center for Biological Evaluation and Research division of the FDA that took place on May 22 regarding RetroSense’s lead product candidate, RST-001 for vision restoration in retinal degenerative conditions.

More From CBS Detroit

Guide: Last Minute Valentine's Day IdeasYou've got less than a week to plan the most romantic night of the year. Better get going!
Best Places To Get A Hot Toddy
Best Sledding Hills

Watch & Listen